Claret Asset Management Corp Red Hill Biopharma Ltd. Transaction History

Claret Asset Management Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	BUY	$0.14 - $695.9 $18,620 - $92.6 Million	133,000 Added 139.37%	228,430 $32,000
Q4 2021 Feb 07, 2022	BUY	$2.31 - $5.85 $75,537 - $191,295	32,700 Added 52.13%	95,430 $246,000
Q3 2021 Dec 02, 2021	BUY	$4.55 - $10.36 $35,298 - $80,372	7,758 Added 14.11%	62,730 $287,000
Q4 2020 Feb 02, 2021	BUY	$7.81 - $10.39 $78,100 - $103,900	10,000 Added 22.24%	54,972 $444,000
Q2 2020 Aug 06, 2020	SELL	$4.6 - $8.6 $114,999 - $215,000	-25,000 Reduced 35.73%	44,972 $301,000
Q1 2020 Apr 06, 2020	SELL	$3.51 - $6.17 $18,006 - $31,652	-5,130 Reduced 6.83%	69,972 $317,000
Q3 2019 Oct 11, 2019	BUY	$6.46 - $8.37 $87,856 - $113,831	13,600 Added 22.11%	75,102 $529,000
Q2 2019 Jul 24, 2019	SELL	$6.34 - $8.8 $38,166 - $52,976	-6,020 Reduced 8.92%	61,502 $400,000
Q4 2018 Feb 07, 2019	BUY	$5.18 - $9.35 $103,600 - $187,000	20,000 Added 42.09%	67,522 $375,000
Q1 2018 May 08, 2018	BUY	$4.96 - $6.84 $24,800 - $34,200	5,000 Added 11.76%	47,522 $246,000
Q4 2017 Mar 27, 2018	BUY	$4.58 - $10.81 $194,750 - $459,662	42,522	42,522 $219,000

40.4K

Ticker RDHL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 63,823,500
Market Cap $465M
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for...

Get notified when there are updates to the investment portfolio of Claret Asset Management Corp, based on Form 13F filings with the SEC.

Stay updated on Claret Asset Management Corp with notifications on news.